Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Stereotaxis, Inc.

Ticker
STXS
Sector
Industry
Report date
November 16, 2026
Valye AI Score

90

Very high visibility
Recent developments
Recent developments summary

Recent developments include strong Q3 2026 revenue growth, FDA clearances, new program launches, and financing activities.

Recent developments:
  • Stereotaxis reported 20% revenue growth in Q3 2026 and secured up to $24 million in convertible note financing [N1].
  • The company held its Q3 2026 earnings call discussing financial results and business strategy [N2].
  • Stereotaxis launched the Genesis Robotic Surgery Program in Hungary for endovascular interventions [N4].
  • The Synchrony System received FDA clearance, supporting expansion in digital surgery offerings [N4].
Overview

Stereotaxis, Inc. develops and markets robotic systems and proprietary disposable devices primarily for electrophysiology and endovascular procedures. The company generates revenue through initial system sales, recurring disposable device sales, software updates, and service contracts. Its contracts often include multiple performance obligations, requiring detailed revenue recognition processes. The company operates in the medical robotics sector with a focus on minimally invasive interventions. Recent FDA clearances and program launches indicate ongoing product development and market expansion efforts.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Stereotaxis, Inc. is a U.S.-based medical robotics company specializing in robotic systems and disposable devices for electrophysiology and endovascular interventions. The company recognizes revenue from system sales, disposables, software updates, and service contracts, with complex revenue recognition due to multiple performance obligations. As of Q3 2026, Stereotaxis reported a net loss of $6.482 million and maintained a current ratio of 1.08. Recent developments include 20% Q3 revenue growth, FDA clearance for the Synchrony System, expansion of digital surgery offerings, and a $24 million convertible note financing [S1][S2][N1][N2][N4].

Scenarios for STXS

Bull case model:

The company has demonstrated revenue growth with a 20% increase in Q3 2026 and secured significant financing to support operations and growth initiatives. FDA clearance of the Synchrony System and expansion into digital surgery programs, including international launches such as in Hungary, highlight product advancement and geographic expansion. The multi-faceted revenue model including disposables and software services supports recurring revenue potential. Strategic partnerships and acquisitions, such as Robocath, may enhance technological capabilities and market reach [N1][N2][N4][S2].

Bear case model:

Stereotaxis reported a net loss of $6.482 million in Q3 2026 and maintains a relatively low cash ratio of 0.13, indicating limited liquidity cushion. The company faces complex revenue recognition challenges due to multiple performance obligations in contracts, which may affect financial reporting clarity. The medical robotics market is competitive with established players, and regulatory approvals are critical but can be uncertain. Risks related to acquisitions and integration, such as Robocath, may impact operational stability [S1][S2].

Moat:

Stereotaxis' moat is based on its proprietary robotic technology and disposable devices tailored for electrophysiology and endovascular interventions. The company's multi-component revenue model, including software and service contracts, creates recurring revenue streams. FDA clearances and regulatory approvals support market access and product differentiation. However, the medical robotics field is competitive and requires continuous innovation and regulatory compliance to maintain market position.

Risks overview
Risks summary
Liquidity constraints combined with complex revenue recognition and competitive pressures represent the primary risks to Stereotaxis' business model and financial stability.
Risks details:

• Liquidity Risk: The company has a cash balance of approximately $3.976 million and a cash ratio of 0.13 as of September 30, 2026, which may limit its ability to cover short-term obligations without additional financing [S2].
• Revenue Recognition Complexity: Contracts with multiple performance obligations require subjective management estimates for revenue recognition, which could lead to financial reporting risks [S1].
• Operational and Integration Risks: Risks related to the acquisition and integration of Robocath and other strategic initiatives may affect business performance [S2].
• Competitive Market: The medical robotics sector is highly competitive, requiring continuous innovation and regulatory compliance to maintain market share.

FINAL FORECAST FOR STXS

Final take one line
Stereotaxis exhibits very high visibility with detailed SEC disclosures and recent news highlighting growth initiatives, product approvals, and financing.
Final take 12 to 24 month view

Business trends: Growth in revenue driven by product launches and geographic expansion, supported by FDA clearances and financing.
Execution milestones: Successful launch of Genesis Robotic Surgery Program in Hungary, FDA clearance of Synchrony System, and securing convertible note financing.
Key risks: Liquidity constraints, complexity in revenue recognition, competitive pressures, and integration risks from acquisitions.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

90
LLM visibility overview
LLM Visibility known facts
  • Stereotaxis, Inc. is a U.S.-based company listed on NYSE American under ticker STXS [S1].
  • The company develops and sells robotic systems and proprietary disposable devices for electrophysiology and endovascular interventions [S1].
  • Revenue is generated from initial system sales, recurring disposable device sales, software updates, and service contracts [S1].
  • Contracts for system sales generally have multiple performance obligations requiring complex revenue recognition judgments [S1].
  • As of September 30, 2026, the company had cash and cash equivalents of $3.976 million and current assets of $34.443 million, with current liabilities of $31.76 million, resulting in a current ratio of 1.08 and a cash ratio of 0.13 [S2].
  • The company reported a net loss of $6.482 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.07 [S2].
  • Stereotaxis reported 20% revenue growth in Q3 2026 and secured up to $24 million in convertible note financing [N1].
  • The company launched the Genesis Robotic Surgery Program in Hungary for endovascular interventions [N4].
  • Stereotaxis received FDA clearance for the Synchrony System and expanded its digital surgery offerings [N4][N2].
  • Recent earnings call transcripts provide detailed discussion of financial results and business strategy [N2][N4].
  • Risk factors disclosed in the 10-K and 10-Q filings include those related to the Robocath acquisition and general operational risks [S2].
Sources
Sources - Context summary

Generated 2026-11-16

Sources - Earning calls
  • N2
  • N4
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-03 | 10-K/A
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-11-11 | www.nasdaq.com | Stereotaxis Reports 20% Q3 Revenue Growth; Secures Up To $24 Million In Convertible Note Financing | https://www.nasdaq.com/articles/stereotaxis-reports-20-q3-revenue-growth-secures-24-million-convertible-note-financing
  • N2 | 2026-11-11 | www.nasdaq.com | Stereotaxis (STXS) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/stereotaxis-stxs-q3-2026-earnings-call-transcript
  • N3 | 2026-09-14 | www.nasdaq.com | Can AI Keep ISRG Ahead of Rising Robotic Surgery Competition? | https://www.nasdaq.com/articles/can-ai-keep-isrg-ahead-rising-robotic-surgery-competition
  • N4 | 2026-08-18 | www.nasdaq.com | Stereotaxis (STXS) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/stereotaxis-stxs-q2-2026-earnings-call-transcript
  • N5 | 2026-08-17 | www.nasdaq.com | Stereotaxis Q2 Widens On Lower Revenue, Higher Expenses; Provides Outlook | https://www.nasdaq.com/articles/stereotaxis-q2-widens-lower-revenue-higher-expenses-provides-outlook
  • N6 | 2026-08-11 | www.nasdaq.com | Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/stereotaxis-inc-stxs-reports-q2-loss-lags-revenue-estimates
  • N7 | 2026-08-06 | www.nasdaq.com | Teleflex (TFX) Surpasses Q2 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/teleflex-tfx-surpasses-q2-earnings-and-revenue-estimates
  • N8 | 2026-08-03 | www.nasdaq.com | Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/si-bone-sibn-reports-q2-loss-tops-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine